These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 26656783)

  • 1. Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: A phase III post-hoc analysis.
    Glauser T; Laurenza A; Yang H; Williams B; Ma T; Fain R
    Epilepsy Res; 2016 Jan; 119():34-40. PubMed ID: 26656783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy.
    Gidal BE; Laurenza A; Hussein Z; Yang H; Fain R; Edelstein J; Kumar D; Ferry J
    Neurology; 2015 May; 84(19):1972-80. PubMed ID: 25878177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
    Gidal BE; Ferry J; Majid O; Hussein Z
    Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes.
    Kwan P; Brodie MJ; Laurenza A; FitzGibbon H; Gidal BE
    Epilepsy Res; 2015 Nov; 117():117-24. PubMed ID: 26448264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
    French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A
    Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
    Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
    Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
    Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A
    Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304.
    French JA; Krauss GL; Biton V; Squillacote D; Yang H; Laurenza A; Kumar D; Rogawski MA
    Neurology; 2012 Aug; 79(6):589-96. PubMed ID: 22843280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multivariable prediction model of a major treatment response for focal-onset seizures: A post-hoc analysis of Phase III trials of perampanel.
    Krauss GL; Ben-Menachem E; Wechsler RT; Patten A; Williams B; Laurenza A; Malhotra M
    Epilepsy Res; 2021 Aug; 174():106649. PubMed ID: 34022524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Perampanel in treatment of refractory partial epilepsy in adolescents and adults: results of international multicenter randomized, double-blind, placebo-controlled phase III studies].
    Belousova ED
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(8):32-8. PubMed ID: 25345628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizures.
    Villanueva V; Majid O; Nabangchang C; Yang H; Laurenza A; Ferry J; Hussein Z
    Epilepsy Res; 2016 Nov; 127():126-134. PubMed ID: 27595590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies.
    Piña-Garza JE; Rosenfeld W; Saeki K; Villanueva V; Yoshinaga H; Patten A; Williams B; Malhotra M
    Epilepsy Behav; 2020 Mar; 104(Pt A):106876. PubMed ID: 31954998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of Liver Toxicity in Perampanel-Treated Subjects: Pooled results from partial seizure phase III perampanel clinical studies.
    Laurenza A; Yang H; Williams B; Zhou S; Ferry J
    Epilepsy Res; 2015 Jul; 113():76-85. PubMed ID: 25986193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures.
    Piña-Garza JE; Lagae L; Villanueva V; Renfroe JB; Laurenza A; Williams B; Kumar D; Meador KJ
    Epilepsy Behav; 2018 Jun; 83():50-58. PubMed ID: 29653338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
    Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A
    Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.
    Krauss GL; Serratosa JM; Villanueva V; Endziniene M; Hong Z; French J; Yang H; Squillacote D; Edwards HB; Zhu J; Laurenza A
    Neurology; 2012 May; 78(18):1408-15. PubMed ID: 22517103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study.
    Rosenfeld W; Conry J; Lagae L; Rozentals G; Yang H; Fain R; Williams B; Kumar D; Zhu J; Laurenza A
    Eur J Paediatr Neurol; 2015 Jul; 19(4):435-45. PubMed ID: 25823975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
    Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
    Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study.
    Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Kaneko S
    Acta Neurol Scand; 2018 Apr; 137(4):392-399. PubMed ID: 29250772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Drug Monitoring for Perampanel in Japanese Epilepsy Patients: Influence of Concomitant Antiepileptic Drugs.
    Yamamoto Y; Usui N; Nishida T; Takahashi Y; Imai K; Kagawa Y; Inoue Y
    Ther Drug Monit; 2017 Aug; 39(4):446-449. PubMed ID: 28703720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.